ATE433495T1 - Invasionsinhibitoren zur verwendung in der wundheilung und krebsbehandlung - Google Patents
Invasionsinhibitoren zur verwendung in der wundheilung und krebsbehandlungInfo
- Publication number
- ATE433495T1 ATE433495T1 AT97949632T AT97949632T ATE433495T1 AT E433495 T1 ATE433495 T1 AT E433495T1 AT 97949632 T AT97949632 T AT 97949632T AT 97949632 T AT97949632 T AT 97949632T AT E433495 T1 ATE433495 T1 AT E433495T1
- Authority
- AT
- Austria
- Prior art keywords
- wound healing
- cancer treatment
- invasion inhibitors
- therapeutic agents
- invasion
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 230000029663 wound healing Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 230000009545 invasion Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000002942 anti-growth Effects 0.000 abstract 1
- 230000002001 anti-metastasis Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000007423 screening assay Methods 0.000 abstract 1
- 239000000758 substrate Substances 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/754,322 US5840514A (en) | 1996-11-21 | 1996-11-21 | Methods of testing cancer and anticancer drugs |
| US08/915,189 US6001965A (en) | 1996-11-21 | 1997-08-20 | Anticancer compounds and methods |
| US08/972,760 US6025150A (en) | 1996-11-21 | 1997-11-18 | Methods and compositions for wound healing |
| PCT/US1997/021674 WO1998022617A1 (en) | 1996-11-21 | 1997-11-20 | Invasion-inducing agents and invasion-inhibitors for use in wound healing and cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE433495T1 true ATE433495T1 (de) | 2009-06-15 |
Family
ID=27419461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97949632T ATE433495T1 (de) | 1996-11-21 | 1997-11-20 | Invasionsinhibitoren zur verwendung in der wundheilung und krebsbehandlung |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0928340B1 (de) |
| AT (1) | ATE433495T1 (de) |
| AU (3) | AU7302298A (de) |
| CA (1) | CA2264570C (de) |
| DE (1) | DE69739449D1 (de) |
| ES (1) | ES2327982T3 (de) |
| WO (1) | WO1998022617A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7179605B2 (en) * | 2001-11-23 | 2007-02-20 | Nanogen Inc. | Fibronectin precursor biopolymer markers indicative of alzheimer's disease |
| JP4313033B2 (ja) * | 2002-12-27 | 2009-08-12 | 株式会社日本点眼薬研究所 | 眼科用治療組成物 |
| WO2006084016A1 (en) | 2005-02-01 | 2006-08-10 | Attenuon, Llc | ACID ADDITION SALTS OF Ac-PHSCN-NH2 |
| EP1843779A2 (de) * | 2005-02-01 | 2007-10-17 | Attenuon, LLC | Zusammensetzungen mit antiangiogenem phscn-peptid |
| AR060040A1 (es) | 2006-03-21 | 2008-05-21 | Genentech Inc | Antagonistas de vefg y de alfa5 beta 1 |
| US8940701B2 (en) * | 2009-05-13 | 2015-01-27 | The Regents Of The University Of Michigan | Compounds for, and methods of, treating cancer and inhibiting invasion and metastases |
| EP3630185A4 (de) | 2017-05-30 | 2020-06-17 | The Board of Trustees of the Leland Stanford Junior University | Behandlung einer neuroinflammatorischen erkrankung |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5492890A (en) * | 1990-12-03 | 1996-02-20 | The Scripps Research Institute | Polypeptides for promoting cell attachment |
| US5773574A (en) * | 1990-12-03 | 1998-06-30 | The Scripps Research Institute | Polypeptides for promoting cell attachment |
| JPH06298797A (ja) * | 1993-04-12 | 1994-10-25 | Fuji Photo Film Co Ltd | ペプチド誘導体およびその用途 |
-
1997
- 1997-11-20 WO PCT/US1997/021674 patent/WO1998022617A1/en not_active Ceased
- 1997-11-20 EP EP97949632A patent/EP0928340B1/de not_active Expired - Lifetime
- 1997-11-20 DE DE69739449T patent/DE69739449D1/de not_active Expired - Lifetime
- 1997-11-20 AT AT97949632T patent/ATE433495T1/de not_active IP Right Cessation
- 1997-11-20 ES ES97949632T patent/ES2327982T3/es not_active Expired - Lifetime
- 1997-11-20 AU AU73022/98A patent/AU7302298A/en not_active Abandoned
- 1997-11-20 CA CA002264570A patent/CA2264570C/en not_active Expired - Fee Related
-
2001
- 2001-06-18 AU AU51984/01A patent/AU765126B2/en not_active Ceased
-
2003
- 2003-12-11 AU AU2003268832A patent/AU2003268832A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998022617A1 (en) | 1998-05-28 |
| EP0928340A1 (de) | 1999-07-14 |
| AU7302298A (en) | 1998-06-10 |
| EP0928340A4 (de) | 2004-08-25 |
| EP0928340B1 (de) | 2009-06-10 |
| ES2327982T3 (es) | 2009-11-05 |
| AU2003268832A1 (en) | 2004-01-22 |
| AU5198401A (en) | 2001-08-16 |
| DE69739449D1 (de) | 2009-07-23 |
| CA2264570C (en) | 2009-01-20 |
| AU765126B2 (en) | 2003-09-11 |
| CA2264570A1 (en) | 1998-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE322290T1 (de) | Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia | |
| DE69831222D1 (de) | Verbindungen zur immundiagnose von prostatakrebs und deren verwendung | |
| DE69724016D1 (de) | Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege | |
| DE60325770D1 (de) | Verwendung von rimexolon zur behandlung von augentrockenheit | |
| DE69414471D1 (de) | Dichtungsanordnung zur Einführung von chirurgischen Instrumenten | |
| DE60032226D1 (de) | Verfahren zur induktion von krebszellentod und tumorregression | |
| DE69600399D1 (de) | Verwendung von einem CGRP Antagonist für dir Behandlung von Hauterythemen neurogenischen Ursprung und erhaltene Zubearbeitung | |
| DE69713295D1 (de) | Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung | |
| DE69927128D1 (de) | Verwendung von topisch applizierbaren Gerinnungsmaterial | |
| EP0709090A3 (de) | Zusammensetzungen zur Behandlung von resistenten Tumoren | |
| NO20014560L (no) | Quinasoliner og terapautisk anvendelse derav | |
| ATE227127T1 (de) | Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes | |
| DE69819006D1 (de) | Verwendung von ginsenoside rb1 zur stimulierung der elastinsynthese | |
| DE69526935D1 (de) | Verwendung von mycobacterium zur tumorbehandlung | |
| DE69804256D1 (de) | Durchsichtiges Zellulosehydrogel und dessen Verwendung | |
| EP0758894A4 (de) | Verwendung von alpha-1c spezifischen verbindungen zur behandlung der benignen prostatahyperplasie | |
| DE59908549D1 (de) | Strahlungsempfindliches Gemisch und dessen Verwendung | |
| DE69739449D1 (de) | Invasionsinhibitoren zur verwendung in der wundheilung und krebsbehandlung | |
| DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| DE69914951D1 (de) | Substituierte tricyclische Verbindungen und deren Verwendung zur Behandlung von sPLA2-bedingten Erkrankungen | |
| DE60027429D1 (de) | Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien | |
| DE69939723D1 (de) | Verwendung von Intereferon Gamma zur Behandlung von Herzhypertrophie | |
| DE69943222D1 (de) | Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b | |
| ATE260278T1 (de) | 5ht1 rezeptor antagonisten und ihre verwendung für die behandlung von depression | |
| DE69701458D1 (de) | Verwendung von buckminsterfulleren zur behandlung neurotoxischer verletzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |